Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-05-28

AUTHORS

Xiaoling Cai, Linong Ji

ABSTRACT

IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to Chinese patients with type 2 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n = 25,411), was examined for eligibility of enrollment in four GLP-1 RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1 RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov). More... »

PAGES

1861-1870

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x

DOI

http://dx.doi.org/10.1007/s13300-021-01079-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1138437570

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34047959


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.411634.5", 
          "name": [
            "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cai", 
        "givenName": "Xiaoling", 
        "id": "sg:person.01070217144.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070217144.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.411634.5", 
          "name": [
            "Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, 100044, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ji", 
        "givenName": "Linong", 
        "id": "sg:person.07521246722.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07521246722.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1602/neurorx.1.3.363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024798661", 
          "https://doi.org/10.1602/neurorx.1.3.363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-017-0981-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084022806", 
          "https://doi.org/10.1007/s00592-017-0981-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-018-0728-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104481176", 
          "https://doi.org/10.1186/s12933-018-0728-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-05-28", 
    "datePublishedReg": "2021-05-28", 
    "description": "IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide\u00a01 receptor agonists (GLP-1\u00a0RAs) to Chinese patients with type\u00a02 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n\u2009=\u200925,411), was examined for eligibility of enrollment in four GLP-1\u00a0RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1\u00a0RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-021-01079-x", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "cardiovascular outcome trials", 
      "diastolic blood pressure", 
      "body mass index", 
      "history of CVD", 
      "duration of diabetes", 
      "prior myocardial infarction", 
      "cardiovascular disease", 
      "baseline characteristics", 
      "Chinese patients", 
      "myocardial infarction", 
      "outcome trials", 
      "blood pressure", 
      "receptor agonist", 
      "GLP-1", 
      "glucagon-like peptide-1 receptor agonists", 
      "peptide-1 receptor agonists", 
      "low-density lipoprotein cholesterol", 
      "glomerular filtration rate", 
      "systolic blood pressure", 
      "glucagon-like peptide", 
      "SUSTAIN 6", 
      "REWIND trial", 
      "weekly dulaglutide", 
      "antidiabetic medications", 
      "lipoprotein cholesterol", 
      "diabetes mellitus", 
      "mass index", 
      "filtration rate", 
      "IntroductionThis study", 
      "exclusion criteria", 
      "type 2", 
      "patients", 
      "representative population", 
      "trials", 
      "HbA1c", 
      "mellitus", 
      "T2DM", 
      "diabetes", 
      "agonists", 
      "age", 
      "enrollment", 
      "population", 
      "duration", 
      "proportion", 
      "EXSCEL", 
      "dulaglutide", 
      "gender", 
      "medications", 
      "infarction", 
      "LDL", 
      "EGFR", 
      "disease", 
      "cholesterol", 
      "history", 
      "ConclusionAmong", 
      "hemoglobin", 
      "ResultsOn", 
      "eligibility", 
      "criteria", 
      "generalizability", 
      "pressure", 
      "peptides", 
      "index", 
      "study", 
      "characteristics", 
      "rate", 
      "results", 
      "inclusion", 
      "basis", 
      "types", 
      "rewind", 
      "E-criterion", 
      "China", 
      "leaders"
    ], 
    "name": "Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus", 
    "pagination": "1861-1870", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1138437570"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-021-01079-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34047959"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-021-01079-x", 
      "https://app.dimensions.ai/details/publication/pub.1138437570"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_896.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-021-01079-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01079-x'


 

This table displays all metadata directly associated to this object as RDF triples.

158 TRIPLES      21 PREDICATES      103 URIs      91 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-021-01079-x schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1103
4 schema:author N45df6175f04c45d8aa67176fa6163eaf
5 schema:citation sg:pub.10.1007/s00592-017-0981-2
6 sg:pub.10.1186/s12933-018-0728-6
7 sg:pub.10.1602/neurorx.1.3.363
8 schema:datePublished 2021-05-28
9 schema:datePublishedReg 2021-05-28
10 schema:description IntroductionThis study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to Chinese patients with type 2 diabetes mellitus (T2DM).MethodsThe 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n = 25,411), was examined for eligibility of enrollment in four GLP-1 RAs CVOTs (Dulaglutide-REWIND, Exenatide-EXSCEL, Liraglutide-LEADER, and Semaglutide-SUSTAIN-6). We first estimated the proportion of 3B population who would meet the six inclusion and exclusion (I/E) criteria, namely age, hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), history of cardiovascular disease (CVD), and antidiabetic medication, in each CVOT. Then we compared 11 baseline characteristics, namely age, gender, duration of diabetes, HbA1c, BMI, eGFR, history of CVD, prior myocardial infarction (MI), low-density lipoprotein cholesterol (LDL-c), diastolic blood pressure (DBP), and systolic blood pressure, between the population in each CVOT and the 3B population. Lastly, we estimated the proportion of 3B population that matched the characteristics in each CVOT population.ResultsOn the basis of the I/E criteria, 31.1% of the 3B population would have been eligible for enrollment in REWIND, 15.0% for SUSTAIN-6, 12.9% for LEADER, and 11.3% for EXSCEL. On the basis of the baseline characteristics, REWIND most closely matched the 3B population on gender, duration of diabetes, HbA1c, DBP, LDL-c, history of CVD, and prior MI. The proportion of 3B population matching on at least eight or at least ten baseline characteristics with CVOT populations was highest for REWIND compared to other CVOTs.ConclusionAmong the four GLP-1 RA CVOTs, the REWIND trial using once-weekly dulaglutide is most generalizable to Chinese patients with T2DM.Trial RegistrationTrial registration: NCT01128205 (www.clinicaltrials.gov).
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf N195a619230fa4c239446e27357577fbb
14 N1ce98cbc5f974590b8cc9d54b328af2d
15 sg:journal.1044057
16 schema:keywords China
17 Chinese patients
18 ConclusionAmong
19 E-criterion
20 EGFR
21 EXSCEL
22 GLP-1
23 HbA1c
24 IntroductionThis study
25 LDL
26 REWIND trial
27 ResultsOn
28 SUSTAIN 6
29 T2DM
30 age
31 agonists
32 antidiabetic medications
33 baseline characteristics
34 basis
35 blood pressure
36 body mass index
37 cardiovascular disease
38 cardiovascular outcome trials
39 characteristics
40 cholesterol
41 criteria
42 diabetes
43 diabetes mellitus
44 diastolic blood pressure
45 disease
46 dulaglutide
47 duration
48 duration of diabetes
49 eligibility
50 enrollment
51 exclusion criteria
52 filtration rate
53 gender
54 generalizability
55 glomerular filtration rate
56 glucagon-like peptide
57 glucagon-like peptide-1 receptor agonists
58 hemoglobin
59 history
60 history of CVD
61 inclusion
62 index
63 infarction
64 leaders
65 lipoprotein cholesterol
66 low-density lipoprotein cholesterol
67 mass index
68 medications
69 mellitus
70 myocardial infarction
71 outcome trials
72 patients
73 peptide-1 receptor agonists
74 peptides
75 population
76 pressure
77 prior myocardial infarction
78 proportion
79 rate
80 receptor agonist
81 representative population
82 results
83 rewind
84 study
85 systolic blood pressure
86 trials
87 type 2
88 types
89 weekly dulaglutide
90 schema:name Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
91 schema:pagination 1861-1870
92 schema:productId N5e833213bb4642efaeb144a01d601bf4
93 N9fa06d50fdd7450688107f2cf6af4a0f
94 Na7e59318728c417ba97ed1c1e19c918d
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138437570
96 https://doi.org/10.1007/s13300-021-01079-x
97 schema:sdDatePublished 2022-09-02T16:05
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N8db4eebc590a4de6b5c5117991a3d171
100 schema:url https://doi.org/10.1007/s13300-021-01079-x
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N195a619230fa4c239446e27357577fbb schema:issueNumber 7
105 rdf:type schema:PublicationIssue
106 N1ce98cbc5f974590b8cc9d54b328af2d schema:volumeNumber 12
107 rdf:type schema:PublicationVolume
108 N45df6175f04c45d8aa67176fa6163eaf rdf:first sg:person.01070217144.87
109 rdf:rest Nefb09b7f2fa6424eb8c38256a4918278
110 N5e833213bb4642efaeb144a01d601bf4 schema:name pubmed_id
111 schema:value 34047959
112 rdf:type schema:PropertyValue
113 N8db4eebc590a4de6b5c5117991a3d171 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N9fa06d50fdd7450688107f2cf6af4a0f schema:name doi
116 schema:value 10.1007/s13300-021-01079-x
117 rdf:type schema:PropertyValue
118 Na7e59318728c417ba97ed1c1e19c918d schema:name dimensions_id
119 schema:value pub.1138437570
120 rdf:type schema:PropertyValue
121 Nefb09b7f2fa6424eb8c38256a4918278 rdf:first sg:person.07521246722.04
122 rdf:rest rdf:nil
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
127 schema:name Cardiorespiratory Medicine and Haematology
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:journal.1044057 schema:issn 1869-6953
133 1869-6961
134 schema:name Diabetes Therapy
135 schema:publisher Springer Nature
136 rdf:type schema:Periodical
137 sg:person.01070217144.87 schema:affiliation grid-institutes:grid.411634.5
138 schema:familyName Cai
139 schema:givenName Xiaoling
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070217144.87
141 rdf:type schema:Person
142 sg:person.07521246722.04 schema:affiliation grid-institutes:grid.411634.5
143 schema:familyName Ji
144 schema:givenName Linong
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07521246722.04
146 rdf:type schema:Person
147 sg:pub.10.1007/s00592-017-0981-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084022806
148 https://doi.org/10.1007/s00592-017-0981-2
149 rdf:type schema:CreativeWork
150 sg:pub.10.1186/s12933-018-0728-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104481176
151 https://doi.org/10.1186/s12933-018-0728-6
152 rdf:type schema:CreativeWork
153 sg:pub.10.1602/neurorx.1.3.363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024798661
154 https://doi.org/10.1602/neurorx.1.3.363
155 rdf:type schema:CreativeWork
156 grid-institutes:grid.411634.5 schema:alternateName Department of Endocrinology and Metabolism, Peking University People’s Hospital, 100044, Beijing, China
157 schema:name Department of Endocrinology and Metabolism, Peking University People’s Hospital, 100044, Beijing, China
158 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...